巩膜外敷贴放射治疗葡萄膜黑色素瘤的临床观察
回顾性系列病例研究纳入819例接受巩膜外敷贴放射治疗(PRT)的葡萄膜黑色素瘤(UM)患者,治疗半年后肿瘤基底最大直径和高度均较治疗前显著缩小,PRT有效率为88.3%,眼球保留率为91.1%,5年转移率12.8%、病死率5.8%。结论认为PRT安全有效,可作为中等大小UM的主要治疗方式。
要点
- PRT治疗UM有效率为88.3%(723/819),眼球保留率为91.1%(723/794)。
- 治疗半年后瘤体基底最大直径和高度均较治疗前显著缩小(P<0.01)。
- 5年肿瘤转移率12.8%、病死率5.8%;10年转移率20.6%、病死率5.8%。
核心结论
- PRT对UM安全、有效,保眼率高且能保存部分有用视力,可作为控制中等大小UM的主要治疗方式。
研究设计与样本
- 回顾性系列病例研究,收集2007年7月至2017年11月在首都医科大学附属北京同仁医院眼科因UM行PRT的819例患者资料。
- 819例中男性408例、女性411例,年龄13~85岁(平均数47岁),均为单眼发病。
- 9例为睫状体黑色素瘤,43例为脉络膜黑色素瘤累及睫状体,767例为脉络膜黑色瘤。
- 819只患眼中中等大小肿瘤697只眼,大肿瘤110只眼;所有患者接受1次PRT,放射治疗时间6~50 d(平均15 d)。
主要发现
- 治疗半年后瘤体基底最大直径为(12.41±3.20)mm,与治疗前(12.82±3.21)mm比较差异有统计学意义(t=2.40,P<0.01)。
- 治疗半年后瘤体高度为(6.18±2.55)mm,与治疗前(7.21±2.57)mm比较差异有统计学意义(t=4.05,P<0.01)。
- 随访时间(34±24)个月(1~125个月),至随访期末25例患者在PRT术后2年失访,71例治疗后行眼球摘除术。
- 视力不变393只眼,视力下降344只眼,视力提高82只眼。
- 60例患者发生全身转移(肝脏、骨、乳腺转移),22例患者因肿瘤全身转移而死亡。
关键数值与推荐
- UM控制标准:以彩色多普勒超声测量瘤体体积与治疗前比较,瘤体高度增加2.0 mm或肿瘤任一边界扩展2.5 mm视为瘤体增长,反之则定义为敷贴治疗有效。
- PRT有效率为88.3%(723/819),眼球保留率为91.1%(723/794)。
- 生存曲线分析显示5年肿瘤转移率为12.8%、病死率为5.8%;10年肿瘤转移率为20.6%、病死率为5.8%。
临床怎么用
- PRT可作为中等大小UM的主要治疗方式,具有较高保眼率并能保存部分有用视力。
- 治疗前后应结合彩色多普勒超声等影像学检查评估瘤体基底最大直径和高度变化以判断疗效。
- 术后需长期随访监测肿瘤转移(肝脏、骨、乳腺等)及视力变化。
局限性
- 本研究为回顾性系列病例研究。
- 随访期末25例患者在PRT术后2年失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the safety and efficacy of external scleral plaque radiotherapy (PRT) in the treatment of uveal melanoma (UM). Methods: This was a retrospective case series study. The data of 819 patients who underwent ophthalmic PRT from July 2007 to November 2017 at Tongren Hospital Affiliated to Beijing Capital Medical University was collected, including preoperative visual acuity, intraocular pressure and slit lamp microscope, color fundus photography, indirect ophthalmoscopy, color Doppler ultrasound, fundus fluorescein angiography, indocyanine green angiography, orbital nuclear magnetic resonance imaging, PRT times and time, complications, follow-up time, the maximum basal diameter and height of the tumor UM half a year after the applicator was removed, tumor metastasis rate, mortality and visual acuity observed at the last follow-up. The tumor growth was considered when the tumor height increased by 2.0 mm or the extension of any boundary of the tumor was 2.5 mm; otherwise, the treatment was defined as effective. The paired t test and Kaplan-Meier survival curve were used for statistical analysis. Results: There were 408 males and 411 females. The age ranged from 13 to 85 years (mean, 47 years). Nine patients had ciliary body melanoma, 43 patients had choroidal melanoma involving the ciliary body, and 767 patients had choroidal melanoma. In all 819 eyes, the tumor was medium-sized in 697 eyes and large in 110 eyes. All patients were treated with PRT only one time. The average radiotherapy time was 15 days (range, 6 to 50 d). All operations were successfully completed, with no active bleeding, infection, adjacent tissue injury and other related complications. At 6 months after the treatment, the maximum basal diameter of the tumor was (12.41±3.20) mm, which was significantly different from that before treatment (12.82±3.21) mm (t=2.40, P<0.01); the tumor height was (6.18±2.55) mm, which was significantly different from that before treatment (7.21±2.57) mm (t=4.05, P<0.01). The average follow-up time was (34±24) months (range, 1 to 125 months). Twenty-five patients lost follow-up at 2 years after the PRT, and 71 patients underwent enucleation. The effective rate of the PRT treatment was 88.3% (723/819), and the eyeball retention rate was 91.1% (723/794). The visual acuity remained stable in 393 eyes, decreased in 344 eyes, and improved in 82 eyes. Sixty patients had systemic metastasis (liver, bone or breast metastasis). Twenty-two patients died of tumor metastasis. The 5-year metastasis rate was 12.8%; the 5-year mortality rate was 5.8%; the 10-year metastasis rate was 20.6%; the 10-year mortality rate was 5.8%. Conclusions: PRT is safe and effective in the treatment for UM and can preserve some useful visual acuity. PRT can be used as the main treatment for medium-sized UM.(Chin J Ophthalmol, 2020, 56: 670-675). 目的: 探讨巩膜外敷贴放射治疗(PRT)对葡萄膜黑色素瘤(UM)的有效性及安全性。 方法: 回顾性系列病例研究。收集自2007年7月至2017年11月在首都医科大学附属北京同仁医院眼科因UM行PRT的共819例患者资料,包括术前视力、眼压以及裂隙灯显微镜、彩色眼底照相、间接检眼镜、彩色多普勒超声、荧光素眼底血管造影、吲哚青绿血管造影、眼眶核磁共振成像检查情况,PRT次数、时间、并发症、随访时间,敷贴器取出后半年UM瘤体的基底最大直径和瘤体高度,末次随访肿瘤转移率、病死率及视力变化情况。UM控制标准:以彩色多普勒超声测量瘤体体积与治疗前相比较,瘤体高度增加2.0 mm或肿瘤任一边界扩展2.5 mm视为瘤体增长,反之则定义为敷贴治疗有效。采用配对t检验及Kaplan-Meier生存曲线进行统计学分析。 结果: 819例UM患者中男性408例,女性411例;年龄13~85岁,平均数为47岁;均为单眼发病,9例为睫状体黑色素瘤,43例为脉络膜黑色素瘤累及睫状体,767例为脉络膜黑色瘤。819只患眼中,中等大小肿瘤697只眼,大肿瘤110只眼。所有患者接受1次PRT,放射治疗时间6~50 d,平均数为15 d。819例患者手术顺利完成,术中无活动性出血,无感染,无邻近组织损伤等相关并发症发生。治疗半年后瘤体基底最大直径为(12.41±3.20)mm,与治疗前瘤体基底最大直径(12.82±3.21)mm比较,差异有统计学意义(t=2.40,P<0.01);治疗半年后瘤体高度为(6.18±2.55)mm,与治疗前瘤体高度(7.21±2.57)mm比较,差异有统计学意义(t=4.05,P<0.01)。随访时间为(34±24)个月(1~125个月),至随访期末25例患者在PRT术后2年失访,71例治疗后行眼球摘除术,PRT的有效率为88.3%(723/819),眼球保留率为91.1%(723/794);视力不变393只眼,视力下降344只眼,视力提高82只眼。60例患者发生全身转移(肝脏、骨、乳腺转移),22例患者因肿瘤全身转移而死亡。生存曲线分析显示5年肿瘤转移率为12.8%,病死率为5.8%;10年肿瘤转移率为20.6%,病死率为5.8%。 结论: PRT对UM安全、有效,保眼率高且能保存部分有用视力,可以作为控制中等大小UM的主要治疗方式。(中华眼科杂志,2020,56:670-675).
引用
- Liu YM, Zhou N, Wei WB, et al. [The clinical observation of external scleral plaque radiotherapy in patients with uveal melanoma]. Zhonghua Yan Ke Za Zhi. 2020. PMID: 32907299. doi:10.3760/cma.j.cn112142-20191121-00588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。